Stämm
San Francisco, US · 16 known investors
Find your way into Stämm
Stämm is a biomanufacturing company founded in 2016 that builds the Bioprocessor, a continuous, bubble-free bioreactor using single-use 3D-printed cartridges for producing monoclonal antibodies, biosimilars, and cell and gene therapies. It serves biologics producers seeking lower costs and scalable, automated manufacturing.
Investors · 16
AIR CapitalBuenos Airesvia Ignacio Peña · inferred
Draper AssociatesSan Mateo · $500K – $5M
Draper CygnusBuenos Aires · $100K – $1M
GRIDXBuenos Aires · $250K
VaranaDenver
Also in the syndicate · 11
Cygnus DraperDecarbonization ConsortiumDragones VCGrid ExponentialNew AbundanceSerenity TradersSOSV's IndieBioTeramipsTrillian LLCVarana CapitalleadVistaEnergy
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AMar 2022 · 2 sources
Varana Capital (lead), Cygnus Draper, Decarbonization Consortium, Dragones VC, Draper Associates, Grid Exponential, New Abundance, Serenity Traders, SOSV's IndieBio, Teramips, Trillian LLC, VistaEnergy
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Stämm do?
- Stämm is a biomanufacturing company founded in 2016 that builds the Bioprocessor, a continuous, bubble-free bioreactor using single-use 3D-printed cartridges for producing monoclonal antibodies, biosimilars, and cell and gene therapies. It serves biologics producers seeking lower costs and scalable, automated manufacturing.
- Who are Stämm's investors?
- Stämm's investors include AIR Capital, Draper Associates, Draper Cygnus, GRIDX, Varana.
- Where is Stämm headquartered?
- Stämm is headquartered in San Francisco, US.